Global Cancer Diagnostics Market Size, Trends and Growth Opportunity, By Type (Imaging Testing, Biomarkers Testing, In Vitro Diagnostic Testing, Biopsy, Others), Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma Cancer, Prostate Cancer, Liver Cancer, Others), End-User (Diagnostic Centres, Hospitals and Clinics, Research Institutes, Others) By Region and forecast till 2027.
Global Cancer Diagnostics Market
Global Cancer Diagnostics Market was valued at USD 172.3 billion in 2022 and is slated to reach at USD 243.6 billion by 2027 at a CAGR of 7.29% from 2022-2027.
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumor in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Market Drivers
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost the global cancer diagnostic market growth. For instance, according to WHO (World Health Organization) cancer is the foremost cause of mortality across the world, which holding account around 9.6 million deaths in 2018. Furthermore, continuous growth of the healthcare and diagnostics sector will positively contribute the market growth during this forecast period. Also, rise in collaborative and independent government as well as private sector initiatives will drive the market growth. Moreover, increase in technological advancements in target disease screening tests will propel the market growth. 
Market Restraints
However, high capital investments and low benefit cost ratio for biomarkers is the major challenging factor which is expected to hinder the global cancer diagnostics market growth. Furthermore, high cost of diagnostic imaging systems will hamper the market growth during this analysis period.
Impact of COVID-19
Government mandates, increased infection rates internationally, and national lockdowns all had a huge financial impact on neurology hospitals and clinics. Due to COVID-19, fewer patients are visiting certain hospitals and clinics, which lessens client engagement. In addition, the COVID-19 situation has delayed a lot of cancer diagnosis procedures. The market for cancer diagnostics has been negatively impacted by the global shortage of medical treatment for illnesses other than COVID-19. However, another element that has a detrimental effect on the market for cancer diagnostics is the restricted supply of medical professionals globally.
Recent developments 
Siemens Healthineers unveiled Magnetom Free in November 2021. The Star whole-body MRI scanner was created to dramatically improve access to magnetic resonance imaging on a global scale.
Agilent Technologies Inc. declared in October 2021 that the European Union has labelled their PD-L1 IHC 22C3 pharmDx test for use in Triple-Negative Breast Cancer (TNBC).
Market Segmentation
Global Cancer Diagnostics Market is segmented into diagnostic type such as Diagnostic Imaging Tests, Biopsy and Cytology Tests, Tumor Biomarkers, and Others. Further, market is segmented into application such as Breast Cancer, Lung Cancer, Cervical Cancer, Kidney Cancer, Pancreatic Cancer, and Others.            Regional Analysis
Also, Global Cancer Diagnostics Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa
Market Key Players
Various key players are discussed in this report such as Becton, Dickinson and Company, GE Healthcare, Abbott, Roche, Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., Illumina, Inc., Siemens Healthcare, and C.R. Bard, Inc.
Market Taxonomy
By Diagnostic Type
• Diagnostic Imaging Tests
• Biopsy and Cytology Tests
• Tumor Biomarkers
• Others
By Application
• Breast Cancer
• Lung Cancer
• Cervical Cancer
• Kidney Cancer
• Pancreatic Cancer
• Others
By End-User 
• Diagnostic Centre
• Hospitals and Clinics
• Research Institutes
• Others
By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa

"
 

Global Cancer Diagnostics Market TOC
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global Cancer Diagnostics Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global Cancer Diagnostics Market, By Diagnostic Type
5.1 Y-o-Y Growth Comparison, By Diagnostic Type 
5.2 Global Cancer Diagnostics Market Share Analysis, By Diagnostic Type 
5.3 Global Cancer Diagnostics Market Size and Forecast, By Diagnostic Type
5.3.1 Diagnostic Imaging Tests
5.3.2 Biopsy and Cytology Tests
5.3.3.Tumor  Biomarkers
5.3.4. Others
6 Global Cancer Diagnostics Market, By Application
6.1 Y-o-Y Growth Comparison, By Application
6.2 Global Cancer Diagnostics Market Share Analysis, By Application
6.3 Global Cancer Diagnostics Market Size and Forecast, By Application
6.3.1 Breast Cancer
6.3.2 Lung Cancer
6.3.3 Cervical Cancer
6.3.4. Kidney Cancer
6.3.5. Pancreatic Cancer
6.3.6. Others
7Global Cancer Diagnostics Market, By Region
7.1 Global Cancer Diagnostics Market Share Analysis, By Region
7.2 Global Cancer Diagnostics Market Share Analysis, By Region
7.3 Global Cancer Diagnostics Market Size and Forecast, By Region
8North America Cancer Diagnostics Market Analysis and Forecast (2022 – 2027)
8.1 Introduction
8.2 North America Cancer Diagnostics Market Share Analysis, By Diagnostic Type
8.3 North America Cancer Diagnostics Market Size and Forecast, By Application
8.4 North America Cancer Diagnostics Market Size and Forecast, By Country
8.4.1 U.S
8.4.2 Canada
8.4.3 Mexico
9Europe Cancer Diagnostics Market Analysis and Forecast (2022 – 2027)
9.1 Introduction
9.2 Europe Cancer Diagnostics Market Share Analysis, By Diagnostic Type 
9.3 Europe Cancer Diagnostics Market Size and Forecast, By Application 
9.4 Europe Cancer Diagnostics Market Size and Forecast, By Country
9.4.1 Germany
9.4.2 France
9.4.3 UK
9.4.4. Rest of Europe
10Asia Pacific Cancer Diagnostics Market Analysis and Forecast (2022 – 2027)
10.1 Introduction
10.2 Asia Pacific Cancer Diagnostics Market Share Analysis, By Diagnostic Type 
10.3 Asia Pacific Cancer Diagnostics Market Size and Forecast, By Application 
10.4 Asia Pacific Cancer Diagnostics Market Size and Forecast, By Country
10.4.1 China
10.4.2 Japan
10.4.3 India
10.4.4. Rest of Asia Pacific
11Latin America Cancer Diagnostics Market Analysis and Forecast (2022 – 2027)
11.1 Introduction
11.2 Latin America Cancer Diagnostics Market Share Analysis, By Diagnostic Type 
11.3 Latin America Cancer Diagnostics Market Size and Forecast, By Application 
11.4 Latin America Cancer Diagnostics Market Size and Forecast, By Country
12Middle East Cancer Diagnostics Market Analysis and Forecast (2022 – 2027)
12.1 Introduction
12.2 Middle East Cancer Diagnostics Market Share Analysis, By Diagnostic Type 
12.3 Middle East Cancer Diagnostics Market Size and Forecast, By Application 
12.4 Middle East Cancer Diagnostics Market Size and Forecast, By Country
13Competitive Analysis
13.1 Competition Dashboard
13.2 Market share Analysis of Top Vendors
13.3 Key Development Strategies
14Company Profiles
15.1 Becton, Dickinson and Company
15.1.1 Overview
15.1.2 Offerings
15.1.3 Key Financials
15.1.4 Business Segment & Geographic Overview
15.1.5 Key Market Developments
15.1.6 Key Strategies
15.2 GE Healthcare
15.2.1 Overview
15.2.2 Offerings
15.2.3 Key Financials
15.2.4 Business Segment & Geographic Overview
15.2.5 Key Market Developments
15.2.6 Key Strategies
15.3 Abbott
15.3.1 Overview
15.3.2 Offerings
15.3.3 Key Financials
15.3.4 Business Segment & Geographic Overview
15.3.5 Key Market Developments
15.3.6 Key Strategies
15.4 Roche
15.4.1 Overview
15.4.2 Offerings
15.4.3 Key Financials
15.4.4 Business Segment & Geographic Overview
15.4.5 Key Market Developments
15.4.6 Key Strategies
15.5 Thermo Fisher Scientific, Inc
15.5.1 Overview
15.5.2 Offerings
15.5.3 Key Financials
15.5.4 Business Segment & Geographic Overview
15.5.5 Key Market Developments
15.5.6 Key Strategies
15.6 Agilent Technologies, Inc
15.6.1 Overview
15.6.2 Offerings
15.6.3 Key Financials
15.6.4 Business Segment & Geographic Overview
15.6.5 Key Market Developments
15.6.6 Key Strategies
15.7 Illumina, Inc
15.7.1 Overview
15.7.2 Offerings
15.7.3 Key Financials
15.7.4 Business Segment & Geographic Overview
15.7.5 Key Market Developments
15.7.6 Key Strategies
15.8 Siemens Healthcare
15.8.1 Overview
15.8.2 Offerings
15.8.3 Key Financials
15.8.4 Business Segment & Geographic Overview
15.8.5 Key Market Developments
15.8.6 Key Strategies
15.9 C.R. Bard, Inc
15.9.1 Overview
15.9.2 Offerings
15.9.3 Key Financials
15.9.4 Business Segment & Geographic Overview
15.9.5 Key Market Developments
15.9.6 Key Strategies

"